Skip to main content
Signal8

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

$INCYPress releaseNov 16, 2026, 4:30 PM ETRead the release

The European Commission approved Incyte's Povofortay (povorcitinib) 45 mg and 75 mg as the first once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa in the EU. Approval rests on the Phase 3 STOP-HS1 and STOP-HS2 trials, which met the HiSCR50 primary endpoint at Week 12, with durable responses through Week 54 (up to 71.4% HiSCR50, 57% HiSCR75, 29% HiSCR100) and no new safety signals.

Key figures

Drug Name
Povofortay (povorcitinib)
Phase Of Trial
Phase 3
Hiscr75 max
57%
Hiscr100 max
29%
Doses approved mg
[45,75]
Hiscr50 week54 max
71.4%
Us approval timing
Q1 2027

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INCY: Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa — AI Analysis | Signal8